Option And License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Arsanis, Inc. – Option and License Agreement (October 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. AMENDMENT NO. 1 to the OPTION AND LICENSE AGREEMENT (October 20th, 2017)
Arsanis, Inc. – Option and License Agreement (September 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Option and License Agreement (August 10th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Isis Pharmaceuticals, Inc. – Strategic Collaboration, Option and License Agreement (May 9th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 5th day of January, 2017 (the "Execution Date") by and between Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea's Affiliates ("Akcea"), andNovartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland ("Novartis"). Novartis and Akcea each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. ("Ionis") and therefore Akcea and Ionis are Affiliates.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (April 10th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (April 5th, 2017)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of August 8, 2016 (Effective Date), by and between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation having an address at 1035 OBrien Drive, Menlo Park, CA 94025 (Adverum), and EDITAS MEDICINE, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (Editas). Adverum and Editas may be referred to herein individually as a Party and collectively as the Parties.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (March 27th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Chimerix Inc. – Patent Option and License Agreement (March 2nd, 2017)

This Agreement is entered into on May 24, 2006 ("EFFECTIVE DATE"), between The Regents of the University of Michigan, a constitutional corporation of the State of Michigan ("MICHIGAN") located at Office of Technology Transfer, 3003 S. State Street, Suite 2071, Ann Arbor, MI 48109-1280, and Chimerix, Inc., a Delaware corporation ("COMPANY"), located at 5007 Southpark Drive, Suite 200, Durham, NC 27713.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (February 13th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Ocular Therapeutix, Inc – Collaboration, Option and License Agreement Between Ocular Therapeutix, Inc. And Regeneron Pharmaceuticals, Inc. (November 9th, 2016)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is made and entered into, effective as of October 10, 2016 (the Effective Date), by and between Ocular Therapeutix, Inc., a corporation organized under the laws of Delaware and having an address at 36 Crosby Drive, Suite 101, Bedford, Massachusetts 01730 (Collaborator), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York and having an address at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (Regeneron). Collaborator and Regeneron are sometimes referred to herein individually as a Party and collectively as the Parties.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (November 8th, 2016)

This Collaboration, Option and License Agreement (the "Agreement") is entered into as of August 8, 2016 ("Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 ("Editas"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement Between Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (Europe) Limited and Crispr Therapeutics Ag Crispr Therapeutics Limited Crispr Therapeutics, Inc. Tracr Hematology Ltd. (October 7th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement Between Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (Europe) Limited and Crispr Therapeutics Ag Crispr Therapeutics Limited Crispr Therapeutics, Inc. Tracr Hematology Ltd. (August 19th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement (July 8th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

Cempra Inc. – Option and License Agreement (June 17th, 2016)

This OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of January 29, 2016 (the Effective Date) by and between Cempra Pharmaceuticals, Inc., a Delaware corporation having an address at 6320 Quadrangle Dr. #360, Chapel Hill, NC 27517 (Cempra), and Macrolide Pharmaceuticals, Inc., a Delaware corporation having an address at 480 Arsenal St., Suite 130, Watertown, MA 02472 (MP). MP and Cempra may be referred to herein individually as a Party or collectively, as the Parties.

Acucela Inc. – Option and License Agreement (May 10th, 2016)

THIS OPTION AND LICENSE AGREEMENT ("Agreement") is made and entered into effective as of March 16, 2016 (the "Effective Date"), by and between ACUCELA INC., a corporation organized under the laws of the State of Washington, USA, having a business address at 1301 Second Avenue, Suite 4200, Seattle, Washington 98101-3805, USA ("Acucela"), and YOUHEALTH EYETECH, INC., a corporation organized under the laws of the State of Delaware, USA, having a business address at 10769 Cherry Hill Drive, San Diego, California 92130, USA ("YouHealth"). In addition, YouHealth's parent company, GUANGZHOU KANG RUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO., LTD., a Chinese company, having a business address at Rui Hou Building F, 6th Floor Guangzhou International Business Incubator Science Park, Guangzhou, 510663 China ("Kangrui"), is signing this Agreement as guarantor of YouHealth's performance of its obligations hereunder and hereby agrees to be bound by the terms of this Agreement to the same extent as Y

Cempra Inc. – Option and License Agreement (February 25th, 2016)

This Option and License Agreement (the "Agreement") is entered into as of January 29, 2016 (the "Effective Date") by and between Cempra Pharmaceuticals, Inc., a Delaware corporation having an address at 6320 Quadrangle Dr. #360, Chapel Hill, NC 27517 ("Cempra"), and Macrolide Pharmaceuticals, Inc., a Delaware corporation having an address at 480 Arsenal St., Suite 130, Watertown, MA 02472 ("MP"). MP and Cempra may be referred to herein individually as a "Party" or collectively, as the "Parties."

Strategic Collaboration, Option and License Agreement (February 16th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of October 26, 2015 (the "Effective Date") by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts ("Vertex Parent"), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales ("Vertex UK" and, together with Vertex Parent, "Vertex") and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland ("CRISPR AG"), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware ("CRISPR Inc."), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales ("CRISPR UK") and TRACR HEMATOLOGY LTD, a UK limited company ("Tracr" and together with CRISPR AG, CRISPR Inc. and CRISPR UK "CRISPR"). Vertex and CRISPR each may be referred to here

Bavarian Nordic A/S / ADR – Option and License Agreement (January 12th, 2016)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made and entered into effective as of 03 March, 2015 (the Effective Date) by and among BAVARIAN NORDIC A/S, a Danish corporation having its principal place of business at Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark (BN) and BAVARIAN NORDIC INC., BNs wholly owned subsidiary, which is a Delaware corporation having its principal place of business at 2425 Garcia Avenue, Mountain View, CA 94043, USA (BNInc), on the one hand, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 USA (BMS), on the other hand. BN and BMS are sometimes referred to herein individually as a Party and collectively as the Parties. BNInc shall be considered a Party and one of the Parties, in each case jointly with BN, only with respect to the BNInc Provisions and shall have no other rights, obligations or liabilities under this Agreement other than as set out in the BNInc Provisions.

Clearside Biomedical, Inc. – Research, Option and License Agreement (January 8th, 2016)

This Research, Option and License Agreement (hereinafter "Agreement"), effective as of April 27, 2015 (the "Effective Date"), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 ("Spark") and Clearside Biomedical, Inc., a Delaware corporation with corporate offices at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA 30005 ("Clearside") (each, a "Party" and collectively, the "Parties").

Bavarian Nordic A/S / ADR – Option and License Agreement (January 4th, 2016)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made and entered into effective as of 03 March, 2015 (the Effective Date) by and among BAVARIAN NORDIC A/S, a Danish corporation having its principal place of business at Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark (BN) and BAVARIAN NORDIC INC., BNs wholly owned subsidiary, which is a Delaware corporation having its principal place of business at 2425 Garcia Avenue, Mountain View, CA 94043, USA (BNInc), on the one hand, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 USA (BMS), on the other hand. BN and BMS are sometimes referred to herein individually as a Party and collectively as the Parties. BNInc shall be considered a Party and one of the Parties, in each case jointly with BN, only with respect to the BNInc Provisions and shall have no other rights, obligations or liabilities under this Agreement other than as set out in the BNInc Provisions.

Clearside Biomedical, Inc. – Research, Option and License Agreement (December 23rd, 2015)

This Research, Option and License Agreement (hereinafter Agreement), effective as of April 27, 2015 (the Effective Date), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (Spark) and Clearside Biomedical, Inc., a Delaware corporation with corporate offices at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA 30005 (Clearside) (each, a Party and collectively, the Parties).

Confidential Treatment Requested by BIND Therapeutics, Inc. THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (December 17th, 2015)

This THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this Amendment) is entered into as of December 8, 2015 (the Third Amendment Effective Date), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) (BIND) and Pfizer Inc. (Pfizer) and amends that certain Research, Option and License Agreement between BIND Biosciences, Inc. and Pfizer, dated as of March 25, 2013 (the Agreement) and amended and restated as of June 12, 2013 and March 31, 2015. Capitalized terms used herein without definition herein shall have the meaning given such terms in the Agreement.

Bavarian Nordic A/S / ADR – Option and License Agreement (November 10th, 2015)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made and entered into effective as of 03 March, 2015 (the Effective Date) by and among BAVARIAN NORDIC A/S, a Danish corporation having its principal place of business at Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark (BN) and BAVARIAN NORDIC INC., BNs wholly owned subsidiary, which is a Delaware corporation having its principal place of business at 2425 Garcia Avenue, Mountain View, CA 94043, USA (BNInc), on the one hand, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 USA (BMS), on the other hand. BN and BMS are sometimes referred to herein individually as a Party and collectively as the Parties. BNInc shall be considered a Party and one of the Parties, in each case jointly with BN, only with respect to the BNInc Provisions and shall have no other rights, obligations or liabilities under this Agreement other than as set out in the BNInc Provisions.

Dimension Therapeutics, Inc. – Option and License Agreement (October 13th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.

CytomX Therapeutics, Inc. – Research Collaboration, Option and License Agreement by and Between Pfizer Inc. And Cytomx Therapeutics, Inc. May 30, 2013 (October 2nd, 2015)

This Research Collaboration, Option and License Agreement (the Agreement) is entered into as of May 30, 2013 (the Effective Date), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (Pfizer) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (CytomX). Pfizer and CytomX may each be referred to herein individually as a Party and collectively as the Parties.

CytomX Therapeutics, Inc. – Research Collaboration, Option and License Agreement by and Between Pfizer Inc. And Cytomx Therapeutics, Inc. May 30, 2013 (September 28th, 2015)

This Research Collaboration, Option and License Agreement (the Agreement) is entered into as of May 30, 2013 (the Effective Date), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (Pfizer) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (CytomX). Pfizer and CytomX may each be referred to herein individually as a Party and collectively as the Parties.

CytomX Therapeutics, Inc. – Research Collaboration, Option and License Agreement by and Between Pfizer Inc. And Cytomx Therapeutics, Inc. May 30, 2013 (September 18th, 2015)

This Research Collaboration, Option and License Agreement (the Agreement) is entered into as of May 30, 2013 (the Effective Date), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (Pfizer) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (CytomX). Pfizer and CytomX may each be referred to herein individually as a Party and collectively as the Parties.

REGENXBIO Inc. – Confidential Treatment Requested Option and License Agreement (September 16th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.

REGENXBIO Inc. – Confidential Treatment Requested Option and License Agreement (September 15th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.

Dimension Therapeutics, Inc. – Option and License Agreement (September 14th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.

CytomX Therapeutics, Inc. – Research Collaboration, Option and License Agreement by and Between Pfizer Inc. And Cytomx Therapeutics, Inc. May 30, 2013 (August 28th, 2015)

This Research Collaboration, Option and License Agreement (the Agreement) is entered into as of May 30, 2013 (the Effective Date), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (Pfizer) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (CytomX). Pfizer and CytomX may each be referred to herein individually as a Party and collectively as the Parties.

REGENXBIO Inc. – Confidential Treatment Requested Option and License Agreement (August 17th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.

Dimension Therapeutics, Inc. – Option and License Agreement (July 17th, 2015)

This OPTION AND LICENSE AGREEMENT (Agreement) is entered into as of March 10, 2015 (the Execution Date), with effectiveness as of February 18, 2014 (the Effective Date), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (Licensor), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (Licensee). Licensor and Licensee are hereinafter referred to individually as a Party and collectively as the Parties.